Kua Whakaaetia te Dato-DXd i Haina mō te Matepukupuku Uma Metastatic HR+, HER2-Negative kua Maimoatia i Mua

I te 22 o Ākuhata, 2025, kua whakaaetia a Datopotamab deruxtecan (Dato-DXd; Datroway) i Haina mō te maimoatanga o ngā tūroro pakeke he mate pukupuku ū kāore e taea te tango, he mate pūkahukahu rānei, he HER2-negative (immunohistochemistry [IHC] 0, IHC 1+, IHC 2+/in situ hybridization [ISH] negative rānei) kua whiwhi i te rongoā endocrine me te iti rawa i te kotahi raina o te chemotherapy i te horopaki matatau.

21f7babaee5b9216646d7acd3c2c0d8c.png

I tēnei wā, he maha tonu ngā whakamātautau haumanu o ngā hangarau hou hei ārai i te matepukupuku i Haina e rapu ana i ngā tūroro. Mēnā kei te hiahia koe ki te kōrero mō ngā rongoā me ngā hangarau hou, ka taea e koe te whakapā atu ki te Tari Ao o te Hōhipera Oncology Rohe Tonga o Beijing.

Tau Waea:4008803716

WeChat ID: 17801183037

Email:myimmnet@163.com

Ko tēnei whakaaetanga i ahu mai i ngā hua pai o te rangahau ā-ao Wāhanga III TROPION-Breast01. I arotakehia e te rangahau ā-ao, wāhanga 3, tuwhera-tapanga, matapōkere TROPION-Breast01 te trophoblast cell surface antigen 2–directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) me te whiringa a te kairangahau mō te chemotherapy (ICC) i roto i te mate pukupuku ū receptor-pai/human epidermal growth factor receptor 2–kino (HR+/HER2–).

I tohaina matapōkeretia ngā tūroro ki te Dato-DXd (n = 365) ki te ICC rānei (n = 367). I whakaitihia e te Dato-DXd te mōrearea o te haere whakamua, te mate rānei ki te ICC (PFS mā te ōwehenga mōrearea BICR [HR], 0.63 [95% CI, 0.52 ki te 0.76]; P < .0001). I kitea te painga PFS ōrite puta noa i ngā rōpū iti. Ahakoa kāore anō kia pakari ngā raraunga OS, i kitea he ia e pai ana ki te Dato-DXd (HR, 0.84 [95% CI, 0.62 ki te 1.14]). Ko te reiti o ngā pānga kino e pā ana ki te maimoatanga (TRAE) taumata ≥3 me te Dato-DXd he iti iho i te ICC (20.8% ki te 44.7%). Ko ngā TRAE tino kitea (ahakoa te momo; momo ≥3) ko te whakapairuaki (51.1%; 1.4%) me te stomatitis (50%; 6.4%) me te Dato-DXd me te neutropenia (te wāhanga rōpū, 42.5%; 30.8%) me te ICC.

I kitea i ngā tūroro e whiwhi ana i te Dato-DXd he whakapainga nui ā-pūtaiao i roto i te PFS me te āhua haumaru pai, ngāwari hoki te whakahaere, ki te whakaritea ki te ICC.

I tēnei wā, he maha tonu ngā whakamātautau haumanu o ngā hangarau hou hei ārai i te matepukupuku i Haina e rapu ana i ngā tūroro. Mēnā kei te hiahia koe ki te kōrero mō ngā rongoā me ngā hangarau hou, ka taea e koe te whakapā atu ki te Tari Ao o te Hōhipera Oncology Rohe Tonga o Beijing.

Tau Waea:4008803716

WeChat ID: 17801183037

Email:myimmnet@163.com

微信图片_20241115181717


Wā tuku: 26 o Ākuhata-2025